Effects of Aldosterone Receptor Antagonist and Angiotensin II Type I Receptor Blocker on Cardiac Transcriptional Factors and mRNA Expression in Rats with Myocardial Infarction

Circulation Journal

Volumn 68, Issue 4, 2004, Pages 376-382

  Matsumoto, Ryo ^a   Yoshiyama, Minoru ^a   Omura, Takashi ^a   Kim, Shokei ^a   Nakamura, Yasuhiro ^a   Izumi, Yasukatsu ^a   Akioka, Kaname ^a   Iwao, Hiroshi ^a   Takeuchi, Kazuhide ^a   Yoshikawa, Junichi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Activator protein 1; Angiotensin II; Cardiac remodeling; Nuclear factor B; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN HEXETIL; COLLAGEN TYPE 1; COLLAGEN TYPE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SPIRONOLACTONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ENZYME ACTIVITY; HEART INFARCTION; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TRANSCRIPTION INITIATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; COLLAGEN TYPE I; COLLAGEN TYPE III; DRUG SYNERGISM; ECHOCARDIOGRAPHY; GENE EXPRESSION PROFILING; HEART; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NF-KAPPA B; RATS; RATS, WISTAR; RECEPTORS, ALDOSTERONE; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; SPIRONOLACTONE; TETRAZOLES; TRANSCRIPTION FACTOR AP-1; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 1842682460     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.376     Document Type: Article

References (30)

1. Weisman HF, Bush DE, Mannisi A, Weisfeldt ML, Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation 1988; 78: 186-201.
2. Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeldt ML. Regional cardiac dilatation after acute myocardial infarction: Recognition by two-dimensional echocardiography. N Engl J Med 1979; 300: 57-62.
3. Weiss JL, Bulkley BH, Hutchins GM, Mason SJ. Two-dimensional echocardiographic recognition of myocardial injury in man: Comparison with postmortem studies. Circulation 1981; 63: 401-408.
4. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990; 81: 1161-1172.
5. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial (The SAVE Investigators). N Engl J Med 1992; 327: 669-677.
6. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598-604.
7. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
8. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial (the Losartan Heart Failure Survival Study ELITE II). Lancet 2000; 355: 1582-1587.
9. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, et al. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension 1999; 33: 961-968.
10. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW Jr, Izumo S, et al. Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci USA 1997; 94: 7543-7548.
11. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.
12. Guillen I, Blanes M, Gomez-Lechon MJ, Castell JV. Cytokine signaling during myocardial infarction: Sequential appearance of IL-1 beta and IL-6. Am J Physiol 1995; 269: R229-R235.
13. Marx N, Neumann FJ, Ott I, Gawaz M, Koch W, Pinkau T, et al. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 165-170.
14. Yoshiyama M, Omura T, Takeuchi K, Kim S, Shimada K, Yamagishi H, et al. Angiotensin blockade inhibits increased JNKs, AP-1 and NF-kappa B DNA-binding activities in myocardial infarcted rats. J Mol Cell Cardiol 2001; 33: 799-810.
15. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES): Rales Investigators. Circulation 2000; 102: 2700-2706.
16. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993; 25: 1369-1380.
17. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701.
18. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Kim S, Takeuchi K, et al. Transmitral inflow pattern assessed by Doppler echocardiography in angiotensin II type 1A receptor knockout mice with myocardial infarction. Circ J 2002; 66: 192-196.
19. Patel AR, Konstam MA. Recent advances in the treatment of heart failure. Circ J 2002; 66: 117-121.
20. Lindpaintner K, Lu W, Neidermajer N, Schieffer B, Just H, Ganten D, et al. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J Mol Cell Cardiol 1993; 25: 133-143.
21. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 1994; 28: 1623-1628.
22. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565.
23. Brilla CG, Rupp H, Funck R, Maisch B. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J 1995; 16(Suppl O): 107-109.
24. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 1995; 27: 1545-1560.
25. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001; 37: 787-793.
26. Hanatani A, Yoshiyama M, Kim S, Omura T, Toda I, Akioka K, et al. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol 1995; 27: 1905-1914.
27. Gidh-Jain M, Huang B, Jain P, Gick G, El-Sherif N. Alterations in cardiac gene expression during ventricular remodeling following experimental myocardial infarction. J Mol Cell Cardiol 1998; 30: 627-637.
28. 2+ exchanger genes between adjacent and remote noninfarcted myocardium after myocardial infarction. J Mol Cell Cardiol 1997; 29: 255-264.
29. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000; 35: 193-201.
30. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000; 36: 330-336.